Acute lymphoblastic leukaemia.
Malard F, Mohty M.
Lancet. 2020 Apr 4;395(10230):1146-1162. doi: 10.1016/S0140-6736(19)33018-1.
Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial.
Jabbour E, Short NJ, Jain N, Huang X, Montalban-Bravo G, Banerjee P, Rezvani K, Jiang X, Kim KH, Kanagal-Shamanna R, Khoury JD, Patel K, Kadia TM, Daver N, Chien K, Alvarado Y, Garcia-Manero G, Issa GC, Haddad FG, Kwari M, Thankachan J, Delumpa R, Macaron W, Garris R, Konopleva M, Ravandi F, Kantarjian H.
Lancet Haematol. 2023 Jan;10(1):e24-e34. doi: 10.1016/S2352-3026(22)00319-2. Epub 2022 Nov 16.
Pediatric relapsed or refractory leukemia: new pharmacotherapeutic developments and future directions.
August KJ, Narendran A, Neville KA.
Drugs. 2013 Apr;73(5):439-61. doi: 10.1007/s40265-013-0026-2.
The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia.
Issa GC, Aldoss I, DiPersio J, Cuglievan B, Stone R, Arellano M, Thirman MJ, Patel MR, Dickens DS, Shenoy S, Shukla N, Kantarjian H, Armstrong SA, Perner F, Perry JA, Rosen G, Bagley RG, Meyers ML, Ordentlich P, Gu Y, Kumar V, Smith S, McGeehan GM, Stein EM.
Nature. 2023 Mar;615(7954):920-924. doi: 10.1038/s41586-023-05812-3. Epub 2023 Mar 15.
Refractory chronic lymphocytic leukemia--new therapeutic strategies.
Schnaiter A, Stilgenbauer S.
Oncotarget. 2010 Nov;1(7):472-482. doi: 10.18632/oncotarget.184.
Guidelines for the management of cytomegalovirus infection in patients with haematological malignancies and after stem cell transplantation from the 2017 European Conference on Infections in Leukaemia (ECIL 7).
Ljungman P, de la Camara R, Robin C, Crocchiolo R, Einsele H, Hill JA, Hubacek P, Navarro D, Cordonnier C, Ward KN; 2017 European Conference on Infections in Leukaemia group.
Lancet Infect Dis. 2019 Aug;19(8):e260-e272. doi: 10.1016/S1473-3099(19)30107-0. Epub 2019 May 29.
Immunotherapies in acute leukemia.
Boissel N, Rabian F.
Therapie. 2022 Mar-Apr;77(2):241-250. doi: 10.1016/j.therap.2021.12.003. Epub 2021 Dec 6.
Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial.
Wang ES, Issa GC, Erba HP, Altman JK, Montesinos P, DeBotton S, Walter RB, Pettit K, Savona MR, Shah MV, Kremyanskaya M, Baer MR, Foran JM, Schiller G, Adès L, Heiblig M, Berthon C, Peterlin P, Rodríguez-Arbolí E, Salamero O, Patnaik MM, Papayannidis C, Grembecka J, Cierpicki T, Clegg B, Ray J, Linhares BM, Nie K, Mitra A, Ahsan JM, Tabachri M, Soifer HS, Corum D, Leoni M, Dale S, Fathi AT.
Lancet Oncol. 2024 Oct;25(10):1310-1324. doi: 10.1016/S1470-2045(24)00386-3.
Approach to patients with primary refractory acute myeloid leukemia.
Orlowski RJ, Mangan JK, Luger SM.
Curr Opin Hematol. 2015 Mar;22(2):97-107. doi: 10.1097/MOH.0000000000000115.
The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML.
Vetrie D, Helgason GV, Copland M.
Nat Rev Cancer. 2020 Mar;20(3):158-173. doi: 10.1038/s41568-019-0230-9. Epub 2020 Jan 6.
